 | • レポートコード：GIR201105653 • 出版社/出版日：GlobalInfoResearch / 2020年10月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医薬品・医療 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、筋緊張性ジストロフィー薬の世界市場を調査対象にし、筋緊張性ジストロフィー薬の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（ISIS-DMPKRx、PRO-135、SRT-152、VAL-0411、その他）、用途別分析（病院、クリニック、家庭用、その他）、市場予測（2021年～2025年）、販売チャンネル・代理店分析情報などを整理しました。 ・市場概要 ・メーカー情報：BioMarin Pharmaceutical Inc.、Isis Pharmaceuticals, Inc.、F. Hoffmann-La Roche Ltd.、Genzyme Corporation、Valentia Biopharma S.L.、Marina Biotech, Inc. ・メーカー別販売量、売上、市場シェア ・筋緊張性ジストロフィー薬の地域別市場分析 ・筋緊張性ジストロフィー薬の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・筋緊張性ジストロフィー薬のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・筋緊張性ジストロフィー薬のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・筋緊張性ジストロフィー薬の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・筋緊張性ジストロフィー薬の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・筋緊張性ジストロフィー薬の種類別市場規模2015-2020：ISIS-DMPKRx、PRO-135、SRT-152、VAL-0411、その他 ・筋緊張性ジストロフィー薬の用途別市場規模2015-2020：病院、クリニック、家庭用、その他 ・筋緊張性ジストロフィー薬の世界市場予測2021-2025：地域別、種類別、用途別 ・販売チャンネル・代理店分析 ・調査の結果・結論 |
Market Overview
The global Myotonic Dystrophy Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Myotonic Dystrophy Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Myotonic Dystrophy Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Myotonic Dystrophy Drug market has been segmented into
ISIS-DMPKRx
PRO-135
SRT-152
VAL-0411
Others
By Application, Myotonic Dystrophy Drug has been segmented into:
Hospital
Clinic
Home Use
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Myotonic Dystrophy Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Myotonic Dystrophy Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Myotonic Dystrophy Drug market.
The report offers in-depth assessment of the growth and other aspects of the Myotonic Dystrophy Drug market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Myotonic Dystrophy Drug Market Share Analysis
Myotonic Dystrophy Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Myotonic Dystrophy Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Myotonic Dystrophy Drug sales, revenue and market share for each player covered in this report.
The major players covered in Myotonic Dystrophy Drug are:
BioMarin Pharmaceutical Inc.
Isis Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Valentia Biopharma S.L.
Marina Biotech, Inc.
Among other players domestic and global, Myotonic Dystrophy Drug market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Myotonic Dystrophy Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Myotonic Dystrophy Drug, with price, sales, revenue and global market share of Myotonic Dystrophy Drug in 2018 and 2019.
Chapter 3, the Myotonic Dystrophy Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Myotonic Dystrophy Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Myotonic Dystrophy Drug market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Myotonic Dystrophy Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Myotonic Dystrophy Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Myotonic Dystrophy Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 ISIS-DMPKRx
1.2.3 PRO-135
1.2.4 SRT-152
1.2.5 VAL-0411
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Myotonic Dystrophy Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Home Use
1.3.5 Others
1.4 Overview of Global Myotonic Dystrophy Drug Market
1.4.1 Global Myotonic Dystrophy Drug Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 BioMarin Pharmaceutical Inc.
2.1.1 BioMarin Pharmaceutical Inc. Details
2.1.2 BioMarin Pharmaceutical Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 BioMarin Pharmaceutical Inc. SWOT Analysis
2.1.4 BioMarin Pharmaceutical Inc. Product and Services
2.1.5 BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Isis Pharmaceuticals, Inc.
2.2.1 Isis Pharmaceuticals, Inc. Details
2.2.2 Isis Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Isis Pharmaceuticals, Inc. SWOT Analysis
2.2.4 Isis Pharmaceuticals, Inc. Product and Services
2.2.5 Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 F. Hoffmann-La Roche Ltd.
2.3.1 F. Hoffmann-La Roche Ltd. Details
2.3.2 F. Hoffmann-La Roche Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 F. Hoffmann-La Roche Ltd. SWOT Analysis
2.3.4 F. Hoffmann-La Roche Ltd. Product and Services
2.3.5 F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Genzyme Corporation
2.4.1 Genzyme Corporation Details
2.4.2 Genzyme Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Genzyme Corporation SWOT Analysis
2.4.4 Genzyme Corporation Product and Services
2.4.5 Genzyme Corporation Myotonic Dystrophy Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Valentia Biopharma S.L.
2.5.1 Valentia Biopharma S.L. Details
2.5.2 Valentia Biopharma S.L. Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Valentia Biopharma S.L. SWOT Analysis
2.5.4 Valentia Biopharma S.L. Product and Services
2.5.5 Valentia Biopharma S.L. Myotonic Dystrophy Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Marina Biotech, Inc.
2.6.1 Marina Biotech, Inc. Details
2.6.2 Marina Biotech, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Marina Biotech, Inc. SWOT Analysis
2.6.4 Marina Biotech, Inc. Product and Services
2.6.5 Marina Biotech, Inc. Myotonic Dystrophy Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Myotonic Dystrophy Drug Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Myotonic Dystrophy Drug Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Myotonic Dystrophy Drug Manufacturer Market Share in 2019
3.3.2 Top 6 Myotonic Dystrophy Drug Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Myotonic Dystrophy Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Myotonic Dystrophy Drug Sales and Market Share by Regions (2015-2020)
4.1.2 Global Myotonic Dystrophy Drug Revenue and Market Share by Regions (2015-2020)
4.2 North America Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
4.3 Europe Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
4.5 South America Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Myotonic Dystrophy Drug Sales, Revenue and Market Share by Country
5.1.1 North America Myotonic Dystrophy Drug Sales and Market Share by Country (2015-2020)
5.1.2 North America Myotonic Dystrophy Drug Revenue and Market Share by Country (2015-2020)
5.2 United States Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
5.3 Canada Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
5.4 Mexico Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Myotonic Dystrophy Drug Sales, Revenue and Market Share by Country
6.1.1 Europe Myotonic Dystrophy Drug Sales and Market Share by Country (2015-2020)
6.1.2 Europe Myotonic Dystrophy Drug Revenue and Market Share by Country (2015-2020)
6.2 Germany Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
6.3 UK Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
6.4 France Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
6.5 Russia Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
6.6 Italy Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Myotonic Dystrophy Drug Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Myotonic Dystrophy Drug Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Myotonic Dystrophy Drug Revenue and Market Share by Regions (2015-2020)
7.2 China Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
7.3 Japan Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
7.4 Korea Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
7.5 India Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
7.7 Australia Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Myotonic Dystrophy Drug Sales, Revenue and Market Share by Country
8.1.1 South America Myotonic Dystrophy Drug Sales and Market Share by Country (2015-2020)
8.1.2 South America Myotonic Dystrophy Drug Revenue and Market Share by Country (2015-2020)
8.2 Brazil Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
8.3 Argentina Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Myotonic Dystrophy Drug Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Myotonic Dystrophy Drug Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Myotonic Dystrophy Drug Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
9.3 Turkey Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
9.4 Egypt Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
9.5 South Africa Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Myotonic Dystrophy Drug Sales and Market Share by Type (2015-2020)
10.2 Global Myotonic Dystrophy Drug Revenue and Market Share by Type (2015-2020)
10.3 Global Myotonic Dystrophy Drug Price by Type (2015-2020)
11 Global Myotonic Dystrophy Drug Market Segment by Application
11.1 Global Myotonic Dystrophy Drug Sales Market Share by Application (2015-2020)
11.2 Global Myotonic Dystrophy Drug Revenue Market Share by Application (2015-2020)
11.3 Global Myotonic Dystrophy Drug Price by Application (2015-2020)
12 Market Forecast
12.1 Global Myotonic Dystrophy Drug Sales, Revenue and Growth Rate (2021-2025)
12.2 Myotonic Dystrophy Drug Market Forecast by Regions (2021-2025)
12.2.1 North America Myotonic Dystrophy Drug Market Forecast (2021-2025)
12.2.2 Europe Myotonic Dystrophy Drug Market Forecast (2021-2025)
12.2.3 Asia-Pacific Myotonic Dystrophy Drug Market Forecast (2021-2025)
12.2.4 South America Myotonic Dystrophy Drug Market Forecast (2021-2025)
12.2.5 Middle East & Africa Myotonic Dystrophy Drug Market Forecast (2021-2025)
12.3 Myotonic Dystrophy Drug Market Forecast by Type (2021-2025)
12.3.1 Global Myotonic Dystrophy Drug Sales Forecast by Type (2021-2025)
12.3.2 Global Myotonic Dystrophy Drug Market Share Forecast by Type (2021-2025)
12.4 Myotonic Dystrophy Drug Market Forecast by Application (2021-2025)
12.4.1 Global Myotonic Dystrophy Drug Sales Forecast by Application (2021-2025)
12.4.2 Global Myotonic Dystrophy Drug Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Myotonic Dystrophy Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Myotonic Dystrophy Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Myotonic Dystrophy Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. BioMarin Pharmaceutical Inc. Basic Information, Manufacturing Base and Competitors
Table 8. BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Major Business
Table 9. BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Total Revenue (USD Million) (2018-2019)
Table 10. BioMarin Pharmaceutical Inc. SWOT Analysis
Table 11. BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Product and Services
Table 12. BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Isis Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 14. Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Major Business
Table 15. Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Total Revenue (USD Million) (2018-2019)
Table 16. Isis Pharmaceuticals, Inc. SWOT Analysis
Table 17. Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Product and Services
Table 18. Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. F. Hoffmann-La Roche Ltd. Basic Information, Manufacturing Base and Competitors
Table 20. F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Major Business
Table 21. F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Total Revenue (USD Million) (2018-2019)
Table 22. F. Hoffmann-La Roche Ltd. SWOT Analysis
Table 23. F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Product and Services
Table 24. F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Genzyme Corporation Basic Information, Manufacturing Base and Competitors
Table 26. Genzyme Corporation Myotonic Dystrophy Drug Major Business
Table 27. Genzyme Corporation Myotonic Dystrophy Drug Total Revenue (USD Million) (2018-2019)
Table 28. Genzyme Corporation SWOT Analysis
Table 29. Genzyme Corporation Myotonic Dystrophy Drug Product and Services
Table 30. Genzyme Corporation Myotonic Dystrophy Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Valentia Biopharma S.L. Basic Information, Manufacturing Base and Competitors
Table 32. Valentia Biopharma S.L. Myotonic Dystrophy Drug Major Business
Table 33. Valentia Biopharma S.L. Myotonic Dystrophy Drug Total Revenue (USD Million) (2018-2019)
Table 34. Valentia Biopharma S.L. SWOT Analysis
Table 35. Valentia Biopharma S.L. Myotonic Dystrophy Drug Product and Services
Table 36. Valentia Biopharma S.L. Myotonic Dystrophy Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Marina Biotech, Inc. Basic Information, Manufacturing Base and Competitors
Table 38. Marina Biotech, Inc. Myotonic Dystrophy Drug Major Business
Table 39. Marina Biotech, Inc. Myotonic Dystrophy Drug Total Revenue (USD Million) (2018-2019)
Table 40. Marina Biotech, Inc. SWOT Analysis
Table 41. Marina Biotech, Inc. Myotonic Dystrophy Drug Product and Services
Table 42. Marina Biotech, Inc. Myotonic Dystrophy Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Global Myotonic Dystrophy Drug Sales by Manufacturer (2018-2019) (K Pcs)
Table 44. Global Myotonic Dystrophy Drug Revenue by Manufacturer (2018-2019) (USD Million)
Table 45. Global Myotonic Dystrophy Drug Sales by Regions (2015-2020) (K Pcs)
Table 46. Global Myotonic Dystrophy Drug Sales Market Share by Regions (2015-2020)
Table 47. Global Myotonic Dystrophy Drug Revenue by Regions (2015-2020) (USD Million)
Table 48. North America Myotonic Dystrophy Drug Sales by Countries (2015-2020) (K Pcs)
Table 49. North America Myotonic Dystrophy Drug Sales Market Share by Countries (2015-2020)
Table 50. North America Myotonic Dystrophy Drug Revenue by Countries (2015-2020) (USD Million)
Table 51. North America Myotonic Dystrophy Drug Revenue Market Share by Countries (2015-2020)
Table 52. Europe Myotonic Dystrophy Drug Sales by Countries (2015-2020) (K Pcs)
Table 53. Europe Myotonic Dystrophy Drug Sales Market Share by Countries (2015-2020)
Table 54. Europe Myotonic Dystrophy Drug Revenue by Countries (2015-2020) (USD Million)
Table 55. Asia-Pacific Myotonic Dystrophy Drug Sales by Regions (2015-2020) (K Pcs)
Table 56. Asia-Pacific Myotonic Dystrophy Drug Sales Market Share by Regions (2015-2020)
Table 57. Asia-Pacific Myotonic Dystrophy Drug Revenue by Regions (2015-2020) (USD Million)
Table 58. South America Myotonic Dystrophy Drug Sales by Countries (2015-2020) (K Pcs)
Table 59. South America Myotonic Dystrophy Drug Sales Market Share by Countries (2015-2020)
Table 60. South America Myotonic Dystrophy Drug Revenue by Countries (2015-2020) (USD Million)
Table 61. South America Myotonic Dystrophy Drug Revenue Market Share by Countries (2015-2020)
Table 62. Middle East & Africa Myotonic Dystrophy Drug Sales by Countries (2015-2020) (K Pcs)
Table 63. Middle East & Africa Myotonic Dystrophy Drug Sales Market Share by Countries (2015-2020)
Table 64. Middle East & Africa Myotonic Dystrophy Drug Revenue by Countries (2015-2020) (USD Million)
Table 65. Middle East & Africa Myotonic Dystrophy Drug Revenue Market Share by Countries (2015-2020)
Table 66. Global Myotonic Dystrophy Drug Sales by Type (2015-2020) (K Pcs)
Table 67. Global Myotonic Dystrophy Drug Sales Share by Type (2015-2020)
Table 68. Global Myotonic Dystrophy Drug Revenue by Type (2015-2020) (USD Million)
Table 69. Global Myotonic Dystrophy Drug Revenue Share by Type (2015-2020)
Table 70. Global Myotonic Dystrophy Drug Sales by Application (2015-2020) (K Pcs)
Table 71. Global Myotonic Dystrophy Drug Sales Share by Application (2015-2020)
Table 72. Global Myotonic Dystrophy Drug Sales Forecast by Regions (2021-2025) (K Pcs)
Table 73. Global Myotonic Dystrophy Drug Market Share Forecast by Regions (2021-2025)
Table 74. Global Myotonic Dystrophy Drug Sales Forecast by Type (2021-2025) (K Pcs)
Table 75. Global Myotonic Dystrophy Drug Market Share Forecast by Type (2021-2025)
Table 76. Global Myotonic Dystrophy Drug Sales Forecast by Application (2021-2025)
Table 77. Global Myotonic Dystrophy Drug Market Share Forecast by Application (2021-2025)
Table 78. Direct Channel Pros & Cons
Table 79. Indirect Channel Pros & Cons
Table 80. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Myotonic Dystrophy Drug Picture
Figure 2. Global Sales Market Share of Myotonic Dystrophy Drug by Type in 2019
Figure 3. ISIS-DMPKRx Picture
Figure 4. PRO-135 Picture
Figure 5. SRT-152 Picture
Figure 6. VAL-0411 Picture
Figure 7. Others Picture
Figure 8. Myotonic Dystrophy Drug Sales Market Share by Application in 2018
Figure 9. Hospital Picture
Figure 10. Clinic Picture
Figure 11. Home Use Picture
Figure 12. Others Picture
Figure 13. Global Myotonic Dystrophy Drug Market Status and Outlook (2015-2025) (USD Million)
Figure 14. United States Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Canada Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Mexico Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Germany Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 18. France Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 19. UK Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Russia Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Italy Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 22. China Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Japan Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Korea Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 25. India Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Southeast Asia Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Australia Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 28. Brazil Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Egypt Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Saudi Arabia Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 31. South Africa Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 32. Turkey Myotonic Dystrophy Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 33. Global Myotonic Dystrophy Drug Sales Market Share by Manufacturer in 2019
Figure 34. Global Myotonic Dystrophy Drug Revenue Market Share by Manufacturer in 2019
Figure 35. Top 3 Myotonic Dystrophy Drug Manufacturer (Revenue) Market Share in 2019
Figure 36. Top 6 Myotonic Dystrophy Drug Manufacturer (Revenue) Market Share in 2019
Figure 37. Key Manufacturer Market Share Trend
Figure 38. Global Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 39. Global Myotonic Dystrophy Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 40. Global Myotonic Dystrophy Drug Revenue Market Share by Regions (2015-2020)
Figure 41. Global Myotonic Dystrophy Drug Revenue Market Share by Regions in 2018
Figure 42. North America Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
Figure 43. Europe Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
Figure 44. Asia-Pacific Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
Figure 45. South America Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
Figure 46. Middle East & Africa Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020)
Figure 47. North America Myotonic Dystrophy Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 48. North America Myotonic Dystrophy Drug Sales Market Share by Countries (2015-2020)
Figure 49. North America Myotonic Dystrophy Drug Sales Market Share by Countries in 2018
Figure 50. North America Myotonic Dystrophy Drug Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 51. North America Myotonic Dystrophy Drug Revenue Market Share by Countries in 2018
Figure 52. United States Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 53. Canada Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 54. Mexico Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 55. Europe Myotonic Dystrophy Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 56. Europe Myotonic Dystrophy Drug Revenue Market Share by Countries (2015-2020)
Figure 57. Europe Myotonic Dystrophy Drug Revenue Market Share by Countries in 2019
Figure 58. Germany Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. UK Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 60. France Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 61. Russia Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 62. Italy Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 63. Asia-Pacific Myotonic Dystrophy Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 64. Asia-Pacific Myotonic Dystrophy Drug Sales Market Share by Regions 2019
Figure 65. Asia-Pacific Myotonic Dystrophy Drug Revenue Market Share by Regions 2019
Figure 66. China Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. Japan Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 68. Korea Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 69. India Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 70. Southeast Asia Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 71. South America Myotonic Dystrophy Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 72. South America Myotonic Dystrophy Drug Sales Market Share by Countries in 2019
Figure 73. South America Myotonic Dystrophy Drug Revenue Market Share by Countries in 2019
Figure 74. Brazil Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 75. Argentina Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 76. Middle East and Africa Myotonic Dystrophy Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 77. Middle East and Africa Myotonic Dystrophy Drug Sales Market Share by Countries in 2019
Figure 78. Middle East and Africa Myotonic Dystrophy Drug Revenue Market Share by Countries (2015-2020)
Figure 79. Middle East and Africa Myotonic Dystrophy Drug Revenue Market Share by Countries in 2019
Figure 80. Saudi Arabia Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 81. Egypt Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 82. Turkey Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 83. South Africa Myotonic Dystrophy Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 84. Global Myotonic Dystrophy Drug Sales and Growth Rate (2021-2025) (K Pcs)
Figure 85. Global Myotonic Dystrophy Drug Revenue and Growth Rate (2021-2025) (USD Million)
Figure 86. North America Sales Myotonic Dystrophy Drug Market Forecast (2021-2025) (K Pcs)
Figure 87. Europe Sales Myotonic Dystrophy Drug Market Forecast (2021-2025) (K Pcs)
Figure 88. Asia-Pacific Sales Myotonic Dystrophy Drug Market Forecast (2021-2025) (K Pcs)
Figure 89. South America Sales Myotonic Dystrophy Drug Market Forecast (2021-2025) (K Pcs)
Figure 90. Middle East & Africa Sales Myotonic Dystrophy Drug Market Forecast (2021-2025) (K Pcs)
Figure 91. Sales Channel: Direct Channel vs Indirect Channel
ベッカー型筋ジストロフィー治療薬の世界市場 2020年 Market Overview The global Becker Muscular Dystrophy Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Becker Muscula…- アンカ血管炎薬の世界市場 2020年 Market Overview The global Anca Vasculitis Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Anca Vasculitis Drug mar…
- コクシジオイデス症薬剤の世界市場 2020年 Market Overview The global Coccidioidomycosis Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Coccidioidomycosis Dr…
- ファンコニ貧血薬の世界市場 2020年 Market Overview The global Fanconi Anemia Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Fanconi Anemia Drug marke…
- 類鼻疽菌感染症治療薬の世界市場 2020年 Market Overview The global Burkholderia Pseudomallei Infections Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Bur…